1. Home
  2. Labeler Index
  3. Rising Pharma Holdings, Inc.
  4. 57237-062
  5. Product Images: Finasteride

Product Images Finasteride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Finasteride NDC 57237-062 by Rising Pharma Holdings, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 Symptom Score in a Long-Term Efficacy and Safety Study - finasteride fig1

Figure 1 Symptom Score in a Long-Term Efficacy and Safety Study - finasteride fig1

This appears to be a table or figure displaying the mean change from baseline and standard error in symptom score for a long term efficacy and safety study involving a placebo and finasteride treatment. The table shows data for the baseline, year 1, year 2, year 3, and year 4 time points. No other information can be inferred from the given text.*

Figure 2 Percent of Patients Having Surgery for BPH, Including TURP - finasteride fig2

Figure 2 Percent of Patients Having Surgery for BPH, Including TURP - finasteride fig2

Figure 4 Prostate Volume in a Long-Term Efficacy and Safety Study - finasteride fig3

Figure 4 Prostate Volume in a Long-Term Efficacy and Safety Study - finasteride fig3

The text refers to Figure 3 and shows the percentage of patients who developed acute urinary retention in both the placebo group and the Finastoride group. It also provides information on the observation time and the number of events and risk per year for each group.*

Figure 5 Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group - finasteride fig4

Figure 5 Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group - finasteride fig4

This is a graph that shows the mean percentage change from baseline in prostate volume over four years in a long-term study that evaluated the efficacy and safety of finasteride compared to a placebo. The data is presented numerically for both treatment groups at each annual timepoint.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (30 Tablets Bottle) - finasteride fig5

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (30 Tablets Bottle) - finasteride fig5

The text represents a figure showing the cumulative incidence of a 4-Point rise in AUA Symptom Score by Treatment Group over time (in years). The graph displays the percentage of individuals experiencing this event, with treatment groups plotted on the x-axis and time on the y-axis. Unfortunately, there is no context about the study or treatments used.*

finasteride fig6

finasteride fig6

This is a description for a medicine called Rising® nocsm7.062.3 Esch fim-costed tablet. The tablet contains an active ingredient called Finasteride and the usual adult dosage is 5mg taken once a day. The medicine is distributed by Fossini-crm R a1. The medicine should not be used by women or children, and pregnant women should avoid this medicine. The pack contains 30 tablets and a circular with more information is included. There is also a printing zone coding area on the pack.*

chemical structure - finasteride str

chemical structure - finasteride str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.